An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Efficacy of Postnatal or Prenatal and Postnatal Intravenous Administration of Allogeneic Expanded Fetal Mesenchymal Stem Cells for the Treatment of Severe Osteogenesis Imperfecta Compared With a Combination of Historical and Untreated Prospective Controls An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Effica ...
Osteogenesis Imperfecta
Biological: BOOST cells
Karolinska Institutet
Karolinska University Hospital;Great Ormond Street Hospital for Children NHS Foundation Trust;University College, London;Universitätsklinikum Köln;UMC Utrecht;Leiden University Medical Center;Lund University Karolinska University Hospital;Great Ormond Street Hospital for Children NHS Foundation Trust;Univer ...
Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones
Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous ...
Osteogenesis Imperfecta
Biological: BOOST cells
Christian Medical College, Vellore, India
Ministry of Science and Technology, India;Vinnova;Karolinska Institutet
Treatment of severe congenital Brittle bone disease after or before and after birth.
An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls. An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and effica ...
Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.;Therapeutic area: Diseases [C ...
Product Name: Expanded human first trimester fetal liver-derived mesenchymal stem cells Product Code: BOOST cellsProduct Name: Expanded human first trimester fetal liver-derived mesenchymal stem cells Product Code: ...
Karolinska Institutet
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
210
Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ...